Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 36
(15_suppl)
◽
pp. e21093-e21093
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Vol 98
(1)
◽
pp. 238-239
◽
Keyword(s):
Keyword(s):
Keyword(s):